Moonlight Therapeutics was founded with the mission to develop safe, effective, and patient-friendly treatments for people suffering from food allergies. The company's core vision is to transform the lives of individuals with food allergies through innovative therapies. Their primary product, MOON101, is a novel intradermal therapy designed to be a best-in-class treatment for peanut allergies. Moonlight Therapeutics focuses on addressing the unmet needs in the food allergy market, aiming to provide a differentiated and superior solution for allergy sufferers.

Notable affiliated people include the team of scientists and medical professionals driving the research and development of their therapies. The company has received significant investment, including a multimillion-dollar clinical trial grant to investigate MOON101 in both adults and children with peanut allergies. Key achievements include advancing MOON101 through critical stages of clinical trials, demonstrating its potential efficacy and safety. Moonlight Therapeutics' overall impact lies in its commitment to breaking through barriers in allergy treatment, offering hope and improved quality of life for those affected by food allergies.